{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:17Z","timestamp":1781179097867,"version":"3.54.1"},"reference-count":24,"publisher":"Scientific Scholar","issue":"03","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>Introduction\u2003Plasma cell leukemia (PCL) is very uncommon and aggressive neoplasm constituting 2 to 4% of all plasma cell dyscrasias. By definition, clonal plasma cells should make up 20% of peripheral blood or have an absolute plasma cell count of 2\u2009\u00d7\u2009109 cells\/cu.mm. PCL can be primary or secondary. In this study, the clinicohematological features of PCL, and correlation of immunophenotypic profile and conventional therapies with overall survival was analyzed.<\/jats:p>\n                  <jats:p>Materials and Methods\u2003This retrospective study involved PCL patients who were diagnosed across a 12-year period, from 2010 to 2021, at a tertiary care center in western India. Clinical, biochemical, peripheral smear, bone marrow aspirate, immunophenotyping, and molecular analysis were performed.<\/jats:p>\n                  <jats:p>Results\u2003Total 39 PCL patients were included in the study among which 36 were primary PCL patients. Splenomegaly (10\/27), hepatomegaly (6\/26), and lymphadenopathy (5\/23) were noted. At presentation, all patients had anemia (&lt;11g\/dL), thrombocytopenia (33\/39), hypercalcemia (&gt;11mg\/dl) 10\/33 (30.3%) and lytic lesions was noted in 18\/26 (69.2%).<\/jats:p>\n                  <jats:p>Immunophenotype of these patients showed CD 38 positivity, CD 138 positivity, CD56 positivity, and CD 117 negativity were 100, 62, 41.6, and 89%, respectively. Overall survival of our patients was 4.1 months and overall survival of patients treated with VTD (bortezomib, thalidomide, dexamethasone) and VCD (bortezomib, cyclophosphamide, dexamethasone) regimen was 3.4 and 4.1 months, respectively, which was not statically significant (p-value 0.816). CD117 and CD56 markers were also not having any prognostic significance (p-value 1.000 and 0.873, respectively).<\/jats:p>\n                  <jats:p>Conclusion\u2003Because of rarity of the disease, prospective studies are very limited and hence management and outcome of the disease are difficult to analyze. The current treatment protocols have no survival advantage and hence newer therapeutic approach is mandatory to attain better outcome.<\/jats:p>","DOI":"10.1055\/s-0043-57231","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T19:00:21Z","timestamp":1686337221000},"page":"280-285","source":"Crossref","is-referenced-by-count":0,"title":["Plasma Cell Leukemia\u2014Clinicopathological Profile from a Tertiary Care Center in Western India"],"prefix":"10.25259","volume":"12","author":[{"given":"Poornima","family":"Manimaran","sequence":"additional","affiliation":[{"name":"Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varnika","family":"Rai","sequence":"additional","affiliation":[{"name":"Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Ranka","sequence":"additional","affiliation":[{"name":"Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Sawhney","sequence":"additional","affiliation":[{"name":"Department of Oncopathology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"ref1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"S H Swerdlow","year":"2008","edition":"4th ed."},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archinte.133.5.813","article-title":"Plasma cell leukemia. Report on 17 cases","volume":"133","author":"R A Kyle","year":"1974","journal-title":"Arch Intern Med"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5045\/br.2016.51.1.23","article-title":"Plasma cell leukemia in North India: retrospective analysis of a distinct clinicohematological entity from a tertiary care center and review of literature","volume":"51","author":"K Bommannan","year":"2016","journal-title":"Blood Res"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-018-0140-1","article-title":"Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma","volume":"8","author":"P Ravi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00277-014-2211-0","article-title":"Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients","volume":"94","author":"G An","year":"2015","journal-title":"Ann Hematol"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"C Fern\u00e1ndez de Larrea","year":"2013","journal-title":"Leukemia"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3324\/haematol.2016.158303","article-title":"Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition","volume":"102","author":"M Granell","year":"2017","journal-title":"Haematologica"},{"issue":"19","key":"ref8","doi-asserted-by":"crossref","first-page":"17543","DOI":"10.18632\/oncotarget.4028","article-title":"Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns","volume":"6","author":"I Cifola","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"C Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000210555","article-title":"A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China","volume":"121","author":"Q Peijing","year":"2009","journal-title":"Acta Haematol"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2991\/chi.k.200706.002","article-title":"Plasma cell leukemia - facts and controversies: more questions than answers?","volume":"2","author":"A Suska","year":"2020","journal-title":"Clin Hematol Int"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.leukres.2018.02.010","article-title":"Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome","volume":"68","author":"C Ganzel","year":"2018","journal-title":"Leuk Res"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12032-007-9011-5","article-title":"Thirty patients with primary plasma cell leukemia: a single center experience","volume":"25","author":"M Colovi\u0107","year":"2008","journal-title":"Med Oncol"},{"issue":"45","key":"ref14","doi-asserted-by":"crossref","first-page":"79517","DOI":"10.18632\/oncotarget.18535","article-title":"The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160)","volume":"8","author":"S H Jung","year":"2017","journal-title":"Oncotarget"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bjh.15092","article-title":"Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients","volume":"180","author":"A Jurczyszyn","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1182\/blood-2012-05-408682","article-title":"How I treat plasma cell leukemia","volume":"120","author":"N W van de Donk","year":"2012","journal-title":"Blood"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cyto.b.20512","article-title":"Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders","volume":"78","author":"B Paiva","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"issue":"18","key":"ref18","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.2016.66.6115","article-title":"Progress in the treatment of primary plasma cell leukemia","volume":"34","author":"P Musto","year":"2016","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11912-019-0754-x","article-title":"Plasma cell leukemia: definition, presentation, and treatment","volume":"21","author":"M T Gundesen","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1309\/AJCP63TOCFNAMDMS","article-title":"The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model","volume":"137","author":"E Cannizzo","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4103\/0377-4929.81603","article-title":"Immunophenotypic profile of plasma cell leukemia: a retrospective study in a reference cancer center in India and review of literature","volume":"54","author":"P R Tembhare","year":"2011","journal-title":"Indian J Pathol Microbiol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5045\/br.2022.2022033","article-title":"Update on primary plasma cell leukemia","volume":"57","author":"S H Jung","year":"2022","journal-title":"Blood Res"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ajh.23339","article-title":"Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles","volume":"88","author":"L Mosca","year":"2013","journal-title":"Am J Hematol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"106687","DOI":"10.1016\/j.leukres.2021.106687","article-title":"Plasma cell leukemia: a review of the molecular classification, diagnosis, and evidenced-based treatment","volume":"111","author":"K Gowin","year":"2021","journal-title":"Leuk Res"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-57231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:12:47Z","timestamp":1781176367000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/plasma-cell-leukemia-clinicopathological-profile-from-a-tertiary-care-center-in-western-india\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":24,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2023,12,1]]},"published-print":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-57231","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}